In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The relationship of renal dysfunction with predictors of chronic heart failure

Session Poster session 1 Saturday 08:30 -17:30

Speaker Elena Reznik

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P255

Authors : E Reznik (Moscow,RU), MS Komissarova (Moscow,RU), SY Soltis (Moscow,RU), GI Storozhakov (Moscow,RU)

15 views

Authors:
E Reznik1 , MS Komissarova1 , SY Soltis1 , GI Storozhakov1 , 1Russian State Medical University - Moscow - Russian Federation ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 53

Purpose: Renal dysfunction is widespread and associated with the poor prognosis in chronic heart failure (CHF). We aimed to estimate the relationship between predictors of CHF and renal function in Russians.

Methods: 175 CHF I-IV NYHA class patients with left ventricular ejection fraction (LVEF, Simpson) <45% without primary renal and oncological diseases were studied. Median (interquartile range) of age was 64.0(56.0-71.0) years; LVEF - 30.8(25.7-37.1) %, 86% males. We analyzed CHF predictors and estimated glomerular filtration rate (eGFR, MDRD and CKD-EPI formulas), 24-hour urinary albumin excretion (UAE). All patients were stable on optimal medical therapy.

Results: CHF was due to coronary artery disease in 81% (1 myocardial infarction (MI) in anamnesis was in 50%, 2 - in 23%, 3 - in 5%), dilated cardiomyopathy - in 9%, arterial hypertension (AH) - in 10% of patients. eGFR was lower in ischemical in comparison with non-ischemical CHF [68.2 (55.0-82.5) vs. 88.2 (65.4-98.6) ml/min/1.73m2, p = 0.006]. Number of MI correlated with eGFR (r = −0.33, p = 0.005). 76% of patients had AH in anamnesis with duration 10 (0-20) years, maximal systolic 180 (115-200) and diastolic 100 (90-110) mm Hg. eGFR was lower [66.8 (50.7-85.3) vs. 82.1 (74.4-97.3) ml/min/1.73m2, p = 0.009] and UAE was higher [50.0 (37.0-78.0) vs. 35.5 (23.6-48.1) mg/24h, p = 0.015] in patients with AH history in comparison with others. Total cholesterol >5.2 mmol/l was in 45%, triglyceride > 1.7 mmol/l - in 17% of patients. Decreased high-density lipoprotein was in 41% of patients and was associated with lower eGFR [50.6 (47.1-59.6) vs. 60.9 (52.8-68.7) ml/min/1.73m2, p = 0.044]. Diabetes mellitus (DM) was in 13.5% of patients. eGFR was lower in these patients vs. with others [54.8 (43.0-60.9) vs. 66.6 (50.5-81.6) ml/min/1.73m2, p = 0.009]. LV hypertrophy (LVH) was in 97%, abdominal obesity - in 68% of patients; 22% had 1st, 6% - 2nd and 1% - 3rd degree of obesity. 37% of patients were current smokers, 57% - smokers in the past. Duration of smoking was 30 (20-38) years, smoker index was 15 (0-30) package/years. 24% were alcohol abusers; frequency of alcohol intake was 4 (1-15) days per month. LVH, obesity, smoking and alcohol abusing weren't associated with renal dysfunction.

Conclusions: Such predictors of chronic heart failure as ischemical etiology, arterial hypertension, dyslipidemia and diabetes mellitus are associated with severity of decreasing of glomerular filtration rate and elevation of urinary albumin excretion and may contribute to progression of cardiorenal syndrome.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are